Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced that it will present at the 43rd Annual J.P. Morgan Healthcare ...

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 ...

Below is Validea's guru fundamental report for MADRIGAL PHARMACEUTICALS INC (MDGL). Of the 22 guru strategies we follow, MDGL rates highest using our Contrarian Investor model based on the ...

Buy MDGL near 285.59 target 335.21 stop loss @ 284.77 Details The technical summary data tells us to buy MDGL near 285.59 with an upside target of 335.21. This data also tells us to set a stop loss @ ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

The Florida Panthers returned home from a long and exhausting road trip only to find themselves playing in overtime on Friday. Florida came from behind to defeat the St. Louis Blues 2-1 on an ...

The stock is currently at $23.26. Madrigal Pharma (MDGL): MDGL is now the largest position by far at ~28% of the portfolio. It was established during Q2 2023 at prices between ~$204 and ~$312.